Cell and gene therapy is colliding with a payment system built for chronic care, not cures
Cell and gene therapies have moved from the edge of science to the center of modern medicine. A single infusion or one-time intervention can replace, repair, or reprogram a faulty biological pathway and, in some cases, deliver a durable response where years of standard treatment never could. For patients with sickle cell disease, spinal muscular atrophy, hemophilia, and certain blood cancers, that shift has already changed what clinicians can reasonably hope to achieve at the bedside.
The problem is not clinical potential. It is financing.
Many of these therapies carry upfront prices that can exceed $4 million per treatment, even as the downstream value may unfold over years. Traditional insurance was built to absorb recurrent costs across a broad population, not to concentrate an enormous bill in a single plan year and a single payer relationship. When a therapy promises long-term benefit but demands immediate payment, the mismatch becomes structural. A patient may change insurers before the long-term benefit is fully realized, while the original payer absorbs most of the initial expense. In that setting, even a therapy with strong clinical logic can become a financial liability no individual insurer wants to own alone.
Health systems face a parallel strain. Specialized cell and gene therapy programs require infrastructure, coordination, and capital before a single patient is treated. The fixed costs of standing up a treatment center can be substantial, and the organization may need to buy, administer, and carry the expense of the drug long before reimbursement arrives. For rare diseases, each case is often negotiated separately. The result is a reimbursement model that rewards caution rather than readiness, even when the patient in front of the clinician has few alternatives.
The stakes extend beyond balance sheets. If payers hesitate, access narrows. If hospitals refuse to build programs, treatment capacity disappears. If manufacturers cannot recoup development costs, the pipeline slows. Innovation then becomes self-limiting: the therapies most capable of changing the trajectory of severe disease are the ones most likely to be trapped by their own success.
A carve-out model could spread risk before the market starts to break
The proposed remedy is to treat cell and gene therapies as a separate financing category rather than folding them into ordinary claims flows. In practical terms, insurers and employers could contribute to a shared fund that covers rare, high-cost cases. Risk would be pooled across purchasers and spread over time, reducing the shock of any single claim and stabilizing premiums for the broader membership. Manufacturers could participate with transparent cost-plus pricing tied to outcome accountability, preserving economic viability while lowering the chance that one payer, one health system, or one patient bears the full burden.
This is a radical departure from the current pattern, but it is not an unfamiliar economic idea. Shared infrastructure is routinely financed through collective arrangements when the benefit is diffuse and the initial capital burden is too large for any single actor. Electricity grids offer one such example: society accepts rate-based financing because the alternative would make the system unaffordable and unevenly available. Cell and gene therapy access faces a similar coordination failure. The therapy may work best when deployed broadly enough to support manufacturer investment, center readiness, and predictable payer participation, yet the costs are being asked to pass through a fragmented system organized around short-term ownership of expense.
One sentence captures the pressure point: the current payment model rewards every participant for acting alone and punishes the system for doing exactly that.
That is why pooling matters. If risk can be distributed across a broader set of purchasers, a payer no longer has to fear that a handful of ultra-expensive cases will distort its entire medical budget. If health systems can coordinate specialized centers rather than build isolated programs for every product, they can preserve access without shouldering unsustainable financial exposure. If manufacturers can rely on a more predictable reimbursement environment, the market becomes more hospitable to continued research and development rather than less.
There is also an important temporal issue. As more therapies enter the market and the supporting infrastructure matures, prices may fall and the financing structure may need to evolve with them. A carve-out model is not meant to freeze the market in its earliest form. It is meant to keep the system from collapsing before that maturation occurs. The structure has to be flexible enough to adjust as the class of drugs becomes more common and as experience accumulates with real-world outcomes, durability, and service delivery.
The risk of inaction is straightforward. Without a workable payment model, insurers will continue to deny or delay authorization, providers will remain reluctant to invest in treatment capacity, and developers will face a market that cannot reliably reward breakthrough science. Patients then lose twice: first at the point of access, and again when future therapies fail to make it through the pipeline because the economics were never made workable.
Cell and gene therapies were built to correct biology. The payment system now has to be rebuilt so it does not undo the clinical promise before patients can reach it.